ICOTYDE Approval Adds New Growth Angle To Johnson & Johnson Valuation Story
unknown📝 Article Content
Johnson & Johnson (NYSE:JNJ) has received U.S. FDA approval for ICOTYDE, an oral IL-23 receptor inhibitor for moderate-to-severe plaque psoriasis. ICOTYDE is the first targeted oral IL-23 inhibitor and offers an alternative to injectable biologics for eligible adult and adolescent patients. The therapy is supported by Phase 3 efficacy and safety data and is part of a broader clinical program in psoriatic arthritis and inflammatory bowel diseases. For investors watching NYSE:JNJ, ICOTYDE...
📄 Summary
Johnson & Johnson (NYSE:JNJ) has received U.S. FDA approval for ICOTYDE, an oral IL-23 receptor inhibitor for moderate-to-severe plaque psoriasis. ICOTYDE is the first targeted oral IL-23 inhibitor and offers an alternative to injectable biologics for eligible adult and adolescent patients. The therapy is supported by Phase 3 efficacy and safety data and is part of a broader clinical program in psoriatic arthritis and inflammatory bowel diseases. For investors watching NYSE:JNJ, ICOTYDE...